

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC

CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

**APPROVAL GRANTED FOR THE COMMENCEMENT OF
CLINICAL TRIALS FOR THE GROUP'S PRODUCTS**

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Group has recently been granted approval from the China Food and Drug Administration to commence clinical trials for the following products developed by the Group.

| Drug Name | Registration Type | Indications |
|------------------------------------------------------|--------------------------|-------------------------------------|
| 1. Paclitaxel for injection (albumin-bound) | Chemical drug type 1.6 | Pancreatic cancer |
| 2. Paclitaxel for injection (albumin-bound) | Chemical drug type 3.4 | Non-small cell lung cancer |
| 3. Vilazodone hydrochloride tablets | Chemical drug type 3.1 | Depression |
| 4. Lurasidone hydrochloride tablets | Chemical drug type 3.1 | Schizophrenia |
| 5. Fosaprepitant dimeglumine for injection | Chemical drug type 3.1 | Nausea |
| 6. Tebipenem pivoxil granules | Chemical drug type 3.1 | Anti-infection |
| 7. Doripenem for injection | Chemical drug type 3.1 | Anti-infection |
| 8. Esomeprazole magnesium enteric-coated capsules | Chemical drug type 5 | Gastro-esophageal reflux disease |
| 9. Gefitinib tablets | Chemical drug type 6 | Non-small cell lung cancer |

| | Drug Name | Registration Type | Indications |
|-----|-----------------------------------------------------------|--------------------------|-----------------------------------------------------------------------------------------|
| 10. | Dasatinib tablets | Chemical drug type 6 | Philadelphia chromosome-positive chronic myelocytic leukemia |
| 11. | Sunitinib malate capsules | Chemical drug type 6 | Kidney cancer; Gastrointestinal stromal tumors; Pancreatic neuroendocrine tumors |
| 12. | Sorafenib tosylate tablets | Chemical drug type 6 | Late stage renal cell carcinoma; Distant metastasis of primary hepatocellular carcinoma |
| 13. | Glipizide extended-release tablets | Chemical drug type 6 | Type II diabetes |
| 14. | Metformin hydrochloride tablets | Chemical drug type 6 | Type II diabetes |
| 15. | Sitagliptin phosphate tablets | Chemical drug type 6 | Type II diabetes |
| 16. | Rabeprazole sodium enteric-coated capsules | Chemical drug type 6 | Gastro-esophageal reflux disease: erosive reflux esophagitis |
| 17. | Lansoprazole enteric-coated capsules | Chemical drug type 6 | Gastro-esophageal reflux disease: erosive reflux esophagitis |
| 18. | Pramipexole hydrochloride tablets | Chemical drug type 6 | Parkinson's disease |
| 19. | Risperidone tablets | Chemical drug type 6 | Schizophrenia |
| 20. | Clopidogrel hydrogen sulfate tablets | Chemical drug type 6 | Prevent the formation of atherosclerosis |
| 21. | Nifedipine controlled-release tablets | Chemical drug type 6 | Hypertension; Coronary heart disease; Chronic stable angina |
| 22. | Rivaroxaban tablets | Chemical drug type 6 | Antithrombotic agent |
| 23. | Ticagrelor tablets | Chemical drug type 6 | Coronary syndrome |
| 24. | Irbesartan hydrochlorothiazide tablets | Chemical drug type 6 | Primary hypertension |
| 25. | Glucosamine hydrochloride capsules | Chemical drug type 6 | Treatment and prevention of osteoarthritis |
| 26. | Amoxicillin and clavulanate potassium tablets | Chemical drug type 6 | Anti-infection |
| 27. | Amoxicillin and clavulanate potassium dispersible tablets | Chemical drug type 6 | Anti-infection |
| 28. | Cefdinir capsules | Chemical drug type 6 | Anti-infection |

The approval for commencement of clinical trials is expected to provide an impetus to the drug development of the Group and lay a foundation for the Group to further enrich its product portfolio.

By Order of the Board
CSPC Pharmaceutical Group Limited
Cai Dongchen
Chairman

Hong Kong, 5 February 2016

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. CHAK Kin Man, Mr. PAN Weidong, Mr. WANG Shunlong, Mr. WANG Huaiyu, Mr. LU Jianmin, Mr. WANG Zhenguo, Mr. WANG Jinxu and Mr. LU Hua as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Mr. LO Yuk Lam and Mr. YU Jinming as independent non-executive directors.